Study shows LYMPHIR plus pembrolizumab yields 24% response rate in tough gynecologic cancers

Citius Oncology announced that a Phase 1 investigator-initiated study combining LYMPHIR (denileukin diftitox-cxdl) with pembrolizumab showed a 24% objective response rate and an average 21.1-month duration of response in patients with relapsed or refractory gynecologic cancers. The study, selected for presentation at the ASCO 2026 meeting, highlights LYMPHIR's potential to enhance immune checkpoint inhibitor efficacy beyond its current use in cutaneous T-cell lymphoma. While early and not designed to prove efficacy, the results suggest LYMPHIR may help overcome resistance to immunotherapy in difficult-to-treat tumors, warranting further research.